Published on 17 Apr 2024 on Zacks via Yahoo Finance
What Makes Immunovant (IMVT) a New Buy Stock
Investors might want to bet on Immunovant, Inc. (IMVT), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.